迪哲医药2025年第三季度净利润亏损2.03亿元

Core Insights - Dige Pharmaceutical reported a significant increase in revenue for Q3 2025, achieving 231 million yuan, which represents a year-on-year growth of 71.46% [1] - Despite the revenue growth, the company recorded a net loss attributable to shareholders of 203 million yuan for Q3 2025 [1] - For the first three quarters of 2025, the total revenue reached 586 million yuan, marking a year-on-year increase of 73.23%, while the net loss attributable to shareholders amounted to 580 million yuan [1]